Articles published by Pharvaris N.V.
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin Symposium
August 28, 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris Announces Annual Meeting of Shareholders
June 11, 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
June 04, 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 10, 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris Announces Extraordinary Meeting of Shareholders
February 16, 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris to Present at the WSAAI Annual Meeting 2024
January 26, 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
January 22, 2024
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
December 06, 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris to Present at the GA²LEN UCARE Conference 2023
November 30, 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
October 30, 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris To Present at the APAAACI 2023 International Conference
October 13, 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris To Present at the CIIC Fall 2023 Conference
October 04, 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
September 19, 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris To Present at the 18th German Allergy Congress
September 06, 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
![](https://ml.globenewswire.com/media/4f758956-d75c-4020-9df0-b14d01115a1b/small/pharvaris-logo-png.png)
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From Pharvaris N.V.
Via GlobeNewswire
Tickers
PHVS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.